CN113825763A - 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用 - Google Patents

一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用 Download PDF

Info

Publication number
CN113825763A
CN113825763A CN202180003252.8A CN202180003252A CN113825763A CN 113825763 A CN113825763 A CN 113825763A CN 202180003252 A CN202180003252 A CN 202180003252A CN 113825763 A CN113825763 A CN 113825763A
Authority
CN
China
Prior art keywords
compound
reaction
rhamnopyranosyl
molar ratio
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180003252.8A
Other languages
English (en)
Inventor
裴钢
夏鹏
李剑峰
李扬
郭飞
杨海利
陆婧
李义
金凯军
王雪松
夏广新
柯樱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CN113825763A publication Critical patent/CN113825763A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种化合物I N‑(β‑L‑吡喃鼠李糖基)阿魏酸酰胺的制备方法，以及所述化合物I在制备用于缓解或治疗受试者中线粒体功能异常和Aβ诱导的线粒体功能异常，治疗抑郁症，改善或提高认知功能的药物中的用途。
Figure DDA0003340789840000011

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202180003252.8A 2020-01-17 2021-01-15 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用 Pending CN113825763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010050922.9A CN113135967B (zh) 2020-01-17 2020-01-17 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用
CN2020100509229 2020-01-17
PCT/CN2021/072054 WO2021143812A1 (zh) 2020-01-17 2021-01-15 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用

Publications (1)

Publication Number Publication Date
CN113825763A true CN113825763A (zh) 2021-12-21

Family

ID=76808226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010050922.9A Active CN113135967B (zh) 2020-01-17 2020-01-17 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用
CN202180003252.8A Pending CN113825763A (zh) 2020-01-17 2021-01-15 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010050922.9A Active CN113135967B (zh) 2020-01-17 2020-01-17 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用

Country Status (2)

Country Link
CN (2) CN113135967B (zh)
WO (1) WO2021143812A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337249A (en) * 1981-08-03 1982-06-29 American Cyanamid Company Modulators of the complement system
CN107141236A (zh) * 2017-04-24 2017-09-08 台州职业技术学院 替卡格雷中间体(1r,2r)‑2‑(3,4‑二氟代苯基)环丙烷腈的新合成方法
CN110117302A (zh) * 2018-02-06 2019-08-13 上海东西智荟生物医药有限公司 神经退行性疾病的治疗药物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591364B (zh) * 2008-05-30 2012-05-23 中国药科大学 氨基糖衍生物、其制法及其医药用途
CN104958287B (zh) * 2015-05-28 2019-01-22 四川大学 一种阿魏酸衍生物作为神经保护药物的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337249A (en) * 1981-08-03 1982-06-29 American Cyanamid Company Modulators of the complement system
CN107141236A (zh) * 2017-04-24 2017-09-08 台州职业技术学院 替卡格雷中间体(1r,2r)‑2‑(3,4‑二氟代苯基)环丙烷腈的新合成方法
CN110117302A (zh) * 2018-02-06 2019-08-13 上海东西智荟生物医药有限公司 神经退行性疾病的治疗药物及其应用

Also Published As

Publication number Publication date
WO2021143812A1 (zh) 2021-07-22
CN113135967A (zh) 2021-07-20
CN113135967B (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
WO2013060258A1 (zh) 伸筋草碱a-c、其制法和其药物组合物与用途
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
EP2763983A1 (en) L-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p3i map kinase inhibitors
US20070237840A1 (en) Therapeutic gastrodia extracts
EP3241824B1 (en) Trifluoroacethydrazide compound as well as preparation method thereof and application thereof in preparing a medicament
AU2020315606A1 (en) Compounds as NLRP3 inflammasome inhibitors and compositions and uses thereof
CN105616400A (zh) 一类牛蒡子苷元氨基甲酸酯衍生物在制备用于治疗阿尔茨海默病的药物中的用途
EP3253766A2 (en) Compounds and methods for preventing or treating sensory hair cell death
CN105622558A (zh) 含苯并呋喃环的酰腙衍生物及其制备方法与应用
WO2017131097A1 (ja) アダマンタン誘導体およびその使用
CN113135967B (zh) 一种N-(β-L-吡喃鼠李糖基)阿魏酸酰胺的制备方法及应用
US20210206714A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN113272298A (zh) 用于治疗呼吸系统疾病的化合物和组合物
US20140121199A1 (en) (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
EP4308097A1 (en) Non-hydroxamate hdac6 inhibitors and related methods of use
WO2022125614A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
KR20090083891A (ko) Ｓ-니트로소티올 화합물 및 관련 유도체
CN114478464B (zh) 一种炎症小体选择性抑制剂及其合成方法和应用
KR102078433B1 (ko) 변비증의 예방 또는 치료약
US10703730B2 (en) Trifluoroacetyl hydrazide compounds and medical uses thereof
WO2017087534A1 (en) Compounds and methods for treating synovial sarcomas
WO2010065571A1 (en) Treatment for glomerulonephritis with 2 - [ 4- ( -7-ethyl-5h-pyrrolo [ 2,3-b ] -pyrazin- 6 -yl) propan-2-ol
KR20090022398A (ko) 2-메틸-2'-하이드록시메틸-6-아미도벤조피란 유도체 또는 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하는 알레르기 질환 치료제
US20220380370A1 (en) Xanthine cb1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination